MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase
- PMID: 23179355
- PMCID: PMC3587367
- DOI: 10.1007/s11481-012-9420-x
MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase
Abstract
3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a popular drug of abuse with well-documented acute effects on serotonergic, dopaminergic, and cholinergic transmitter systems, as well as evidence of long-term disruption of serotoninergic systems in the rat brain. Recently, it was demonstrated that MDMA evokes a delayed and sustained increase in glutamate release in the hippocampus. The purpose of the present study was to determine the role of inflammatory mediators in the MDMA-induced increase in glutamate release, as well as the contribution of inflammatory pathways in the persistent neurochemical toxicity associated with repeated MDMA treatment. Treatment with the non-selective cyclooxygenase (COX) inhibitor ketoprofen and the COX-2 selective inhibitor nimesulide attenuated the increase in extracellular glutamate in the hippocampus evoked by repeated MDMA exposure (10 mg/kg, i.p., every 2 h); no attenuation was observed in rats treated with the COX-1 selective inhibitor piroxicam. Reverse dialysis of a major product of COX activity, prostaglandin E2, also resulted in a significant increase in extracellular glutamate in the hippocampus . Repeated exposure to MDMA diminished the number of parvalbumin-positive GABA interneurons in the dentate gyrus of the hippocampus, an effect that was attenuated by ketoprofen treatment. However, COX inhibition with ketoprofen did not prevent the long-term depletion of 5-HT in the hippocampus evoked by MDMA treatment. These data are supportive of the view that cyclooxygenase activity contributes to the mechanism underlying both the increased release of glutamate and decreased number of GABA interneurons in the rat hippocampus produced by repeated MDMA exposure.
Figures



Similar articles
-
MDMA-induced loss of parvalbumin interneurons within the dentate gyrus is mediated by 5HT2A and NMDA receptors.Eur J Pharmacol. 2015 Aug 15;761:95-100. doi: 10.1016/j.ejphar.2015.04.035. Epub 2015 Apr 30. Eur J Pharmacol. 2015. PMID: 25936514 Free PMC article.
-
3,4-methylenedioxymethamphetamine increases excitability in the dentate gyrus: role of 5HT2A receptor-induced PGE2 signaling.J Neurochem. 2016 Mar;136(5):1074-84. doi: 10.1111/jnc.13493. Epub 2016 Jan 19. J Neurochem. 2016. PMID: 26670377 Free PMC article.
-
MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus.Neuropharmacology. 2012 Nov;63(6):1022-7. doi: 10.1016/j.neuropharm.2012.07.026. Epub 2012 Jul 25. Neuropharmacology. 2012. PMID: 22842073 Free PMC article.
-
Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.Pharmacol Biochem Behav. 2008 Aug;90(2):198-207. doi: 10.1016/j.pbb.2007.10.003. Epub 2007 Oct 16. Pharmacol Biochem Behav. 2008. PMID: 18035407 Free PMC article. Review.
-
3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions.J Pharmacol Exp Ther. 2001 Jun;297(3):846-52. J Pharmacol Exp Ther. 2001. PMID: 11356903 Review.
Cited by
-
Novel Pharmacological Targets of Post-Traumatic Stress Disorders.Life (Basel). 2023 Aug 11;13(8):1731. doi: 10.3390/life13081731. Life (Basel). 2023. PMID: 37629588 Free PMC article. Review.
-
Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity.Neurotox Res. 2018 Nov;34(4):763-768. doi: 10.1007/s12640-018-9892-4. Epub 2018 Apr 9. Neurotox Res. 2018. PMID: 29629511
-
Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage.Neurotox Res. 2017 Nov;32(4):563-574. doi: 10.1007/s12640-017-9761-6. Epub 2017 Jun 9. Neurotox Res. 2017. PMID: 28597409
-
Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.Neural Regen Res. 2020 May;15(5):802-816. doi: 10.4103/1673-5374.268895. Neural Regen Res. 2020. PMID: 31719240 Free PMC article. Review.
-
Neuropsychological, Neurovirological and Neuroimmune Aspects of Abnormal GABAergic Transmission in HIV Infection.J Neuroimmune Pharmacol. 2016 Jun;11(2):279-93. doi: 10.1007/s11481-016-9652-2. Epub 2016 Jan 30. J Neuroimmune Pharmacol. 2016. PMID: 26829944 Free PMC article.
References
-
- Armstrong BD, Noguchi KK. The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: An in-vitro autoradiographic study in rats. Neurotoxicology. 2004;25:905–914. - PubMed
-
- Asanuma M, Tsuji T, Miyazaki I, Miyoshi K, Ogawa N. Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug. Neurosci Lett. 2003;352:13–16. - PubMed
-
- Asi SS, Farhadi HM, Mousavizadeh K, Samadikuchaksaraei A, Soleimani M, Jameie SB, Joghataei MT, Samzadeh-Kermani A, Hashemi-Nasl H, Mehdizadeh M. Evaluation of Bcl-2 Family Gene Expression in Hippocampus of 3,4-methylenedioxymethamphetamine Treated Rats. Cell Journal. 2012 2012 Winter13(4) - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials